Based on its ability to inhibit EGFR signaling by binding to dimerization domain II, block the PD-1/PD-L1 interaction and mediate specific cellular recognition to EGFR/PD-L1 double-positive tumor cells, HCP-LCE was chosen as a starting molecule to introduce a NK cell engaging module. This evidence concerns the gene EGFR and neoplasm.